These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36358171)

  • 1. Bioengineered Nisin A Derivatives Display Enhanced Activity against Clinical Neonatal Pathogens.
    Desmond A; O'Halloran F; Cotter L; Hill C; Field D
    Antibiotics (Basel); 2022 Oct; 11(11):. PubMed ID: 36358171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bioengineered derivative of nisin displays enhanced antimicrobial activity against clinical Streptococcus agalactiae isolates.
    Hayes K; Field D; Hill C; O'Halloran F; Cotter L
    J Glob Antimicrob Resist; 2019 Dec; 19():14-21. PubMed ID: 31054335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bioengineered Nisin Derivative To Control Streptococcus uberis Biofilms.
    Pérez-Ibarreche M; Field D; Ross RP; Hill C
    Appl Environ Microbiol; 2021 Jul; 87(16):e0039121. PubMed ID: 34105992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioengineered Nisin Derivative M17Q Has Enhanced Activity against
    Twomey E; Hill C; Field D; Begley M
    Antibiotics (Basel); 2020 Jun; 9(6):. PubMed ID: 32517174
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic effect of two antimicrobial peptides, Nisin and P10 with conventional antibiotics against extensively drug-resistant Acinetobacter baumannii and colistin-resistant Pseudomonas aeruginosa isolates.
    Jahangiri A; Neshani A; Mirhosseini SA; Ghazvini K; Zare H; Sedighian H
    Microb Pathog; 2021 Jan; 150():104700. PubMed ID: 33346078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro synergistic activity of erythromycin and nisin against clinical Group B Streptococcus isolates.
    Hayes K; Cotter L; O'Halloran F
    J Appl Microbiol; 2019 Nov; 127(5):1381-1390. PubMed ID: 31342602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Activities of Nisin and Nisin Derivatives Alone and In Combination with Antibiotics against Staphylococcus Biofilms.
    Field D; O' Connor R; Cotter PD; Ross RP; Hill C
    Front Microbiol; 2016; 7():508. PubMed ID: 27148197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of combinations of rationally selected bioengineered nisin derivatives for their ability to inhibit Listeria in broth and model food systems.
    Nyhan L; Field D; Hill C; Callanan M; Begley M
    Food Microbiol; 2021 Oct; 99():103835. PubMed ID: 34119119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value addition in the efficacy of conventional antibiotics by Nisin against Salmonella.
    Singh AP; Prabha V; Rishi P
    PLoS One; 2013; 8(10):e76844. PubMed ID: 24116175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of antimicrobial cationic peptides; melittin and nisin, alone or in combination with antibiotics against Gram-positive bacteria.
    Dosler S; Gerceker AA
    J Chemother; 2012 Jun; 24(3):137-43. PubMed ID: 22759757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of nisin against the swine pathogen Streptococcus suis and its synergistic interaction with antibiotics.
    Lebel G; Piché F; Frenette M; Gottschalk M; Grenier D
    Peptides; 2013 Dec; 50():19-23. PubMed ID: 24096107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The N-terminal Region of Nisin Is Important for the BceAB-Type ABC Transporter NsrFP from
    Reiners J; Lagedroste M; Ehlen K; Leusch S; Zaschke-Kriesche J; Smits SHJ
    Front Microbiol; 2017; 8():1643. PubMed ID: 28912758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro synergistic activities of cefazolin and nisin A against mastitis pathogens.
    Kitazaki K; Koga S; Nagatoshi K; Kuwano K; Zendo T; Nakayama J; Sonomoto K; Ano H; Katamoto H
    J Vet Med Sci; 2017 Sep; 79(9):1472-1479. PubMed ID: 28757508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V.
    Field D; Quigley L; O'Connor PM; Rea MC; Daly K; Cotter PD; Hill C; Ross RP
    Microb Biotechnol; 2010 Jul; 3(4):473-86. PubMed ID: 21255345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A bioengineered nisin derivative to control biofilms of Staphylococcus pseudintermedius.
    Field D; Gaudin N; Lyons F; O'Connor PM; Cotter PD; Hill C; Ross RP
    PLoS One; 2015; 10(3):e0119684. PubMed ID: 25789988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic foot infections: Application of a nisin-biogel to complement the activity of conventional antibiotics and antiseptics against Staphylococcus aureus biofilms.
    Santos R; Ruza D; Cunha E; Tavares L; Oliveira M
    PLoS One; 2019; 14(7):e0220000. PubMed ID: 31339915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in vitro study on the effects of nisin on the antibacterial activities of 18 antibiotics against Enterococcus faecalis.
    Tong Z; Zhang Y; Ling J; Ma J; Huang L; Zhang L
    PLoS One; 2014; 9(2):e89209. PubMed ID: 24586598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nisin J, a Novel Natural Nisin Variant, Is Produced by Staphylococcus capitis Sourced from the Human Skin Microbiota.
    O'Sullivan JN; O'Connor PM; Rea MC; O'Sullivan O; Walsh CJ; Healy B; Mathur H; Field D; Hill C; Ross RP
    J Bacteriol; 2020 Jan; 202(3):. PubMed ID: 31740495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of nisin-β-lactam antibiotics against clinical strains of Salmonella enterica serovar Typhi.
    Rishi P; Preet Singh A; Garg N; Rishi M
    J Antibiot (Tokyo); 2014 Dec; 67(12):807-11. PubMed ID: 24961707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The generation of nisin variants with enhanced activity against specific gram-positive pathogens.
    Field D; Connor PM; Cotter PD; Hill C; Ross RP
    Mol Microbiol; 2008 Jul; 69(1):218-30. PubMed ID: 18485077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.